Make informed decisions that maximize technology commercial potential and probability of success
Secure investment with analyses that quantify the value of technology for the payer
Obtain technology trial within target health systems
Secure adoption of technology that has been developed
Not decided on lead clinical application or target patient group
Decided, but not sure of commercial potential and evidence required to bring to market
Somewhat sure of commercial potential, but need to quantify attractiveness to payer and pricing
Understand payer dynamics and seeking trial to generate evidence
Evidence developed and ready to seek procurement
Connect with us to find out more
Demonstrate your future commercial potential
Provide potential investors with a clear understanding of the investment opportunity
Ensure the successful translation of research into practice
Expert advice and analysis at your fingertips
Connect with our partner agencies to help you grow
Discover VC partners to achieve your goals
Design and deploy trials across our network
Join our network to discover new opportunities
Learn more about the project behind the platform
Learn more about us
Colors, logos, and standards
Explore help and support articles
ASSESS has been created by a Leadership Team with deep experience in life sciences technology evaluation and commercialization.
Concurrent with his role at ASSESS, Professor McCabe has lead responsibility for Queens University Belfast’s Belfast Region City Deal Programme. Powered by over £170 million of investment from the UK government, the programme will deliver Innovation Centres in Deep Tech, Advanced Manufacturing and the Life Sciences, to create jobs and drive inclusive economic growth across Northern Ireland. Previously, he was the CEO of the Institute of Health Economics in Alberta, Canada, and Professor of Health Economics at the University of Alberta.
He has 30 years experience as a health economist working in the area of economic evaluation and health technology assessment. He has contributed to several standard setting documents related to the evaluation of innovative health technologies both nationally and internationally, including the second edition of the NICE Guide to the Methods of Health Technology Appraisal, the fourth edition of the CADTH Guidelines for the Economic Evaluation of Health Technologies, and third edition of the ISSC Guidelines for the translation of stem cell research and regenerative medicine. He has been an expert witness to both the UK and Canadian House of Commons Health committees and recently advised Canada’s Patented Medicines Price Review Board on the development of Value Based Pricing for patented drugs in Canada.
Previously, he was Director of Industry Partnerships at the Institute of Health Economics, a research institute located in Alberta, Canada. Following completion of a Master of Public Health degree from the University of Alberta, Dan began his career in the pharmaceutical industry, holding progressive leadership positions in Commercial and Government Relations roles. He then served as Vice President, Commercialization, for what became one of Canada’s leading electronic medical record companies. He led the company from early growth to acquisition by one of Canada’s largest corporations. He is Board member of The Health Data Coalition, and past Board Member of the Canadian Association for Population Therapeutics, and an Advisor to a number of organizations in the health innovation ecosystem.
Contact us to learn more about how insights from ASSESS can help your organization to inform investor decision-making and improve valuation and probability of capital raise success.